Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1995 1
2002 1
2003 1
2010 1
2012 2
2013 3
2014 1
2016 1
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Ovarian Transitional Cell Carcinoma"
Page 1
Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer.
Mackay HJ, Brady MF, Oza AM, Reuss A, Pujade-Lauraine E, Swart AM, Siddiqui N, Colombo N, Bookman MA, Pfisterer J, du Bois A; Gynecologic Cancer InterGroup. Mackay HJ, et al. Int J Gynecol Cancer. 2010 Aug;20(6):945-52. doi: 10.1111/IGC.0b013e3181dd0110. Int J Gynecol Cancer. 2010. PMID: 20683400 Review.
Serous acted as the reference histology, and a proportional hazards model was used to estimate the relative rate of progression or death. RESULTS: Data on 8704 women with stage III/IV EOC from 7 randomized trials were included in these analyses. Two hundred twenty-one pati …
Serous acted as the reference histology, and a proportional hazards model was used to estimate the relative rate of progression or death. RE …
New insights on the pathogenesis of ovarian carcinoma: molecular basis and clinical implications.
Gadducci A, Guerrieri ME, Genazzani AR. Gadducci A, et al. Gynecol Endocrinol. 2012 Aug;28(8):582-6. doi: 10.3109/09513590.2011.649595. Epub 2012 Feb 4. Gynecol Endocrinol. 2012. PMID: 22304686
Ovarian carcinoma can be subdivided into two categories termed type I and type II. ...For instance, BRAF inhibitors could be used in low-grade serous carcinomas, PIK3CA inhibitors could be employed in clear cell carcinoma, and poly (ADP-ribose) polymer …
Ovarian carcinoma can be subdivided into two categories termed type I and type II. ...For instance, BRAF inhibitors could be u …
Renal-ovarian axis: a case report and review.
Gavallos G, Tawfik O, Herrell D, Langenstroer P. Gavallos G, et al. Urology. 2003 Oct;62(4):749. doi: 10.1016/s0090-4295(03)00585-5. Urology. 2003. PMID: 14550464 Review.
The renal-ovarian axis is a unique and rare phenomenon manifested by an interesting interrelationship between the ovary and kidney. ...A poor understanding of this metastatic spread has led to missed, or delayed, diagnosis of the primary malignancy. We describe the only ca …
The renal-ovarian axis is a unique and rare phenomenon manifested by an interesting interrelationship between the ovary and kidney. . …
Ovarian carcinomas with transitional cell carcinoma pattern.
Silva EG, Robey-Cafferty SS, Smith TL, Gershenson DM. Silva EG, et al. Am J Clin Pathol. 1990 Apr;93(4):457-65. doi: 10.1093/ajcp/93.4.457. Am J Clin Pathol. 1990. PMID: 2321577
The authors report 88 cases of ovarian carcinoma containing areas of transitional cell carcinoma (TCC). ...Tumor recurrences and lack of response to chemotherapy are often associated with a change in the histologic appearance of the metas …
The authors report 88 cases of ovarian carcinoma containing areas of transitional cell carcinoma (TCC). . …
Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
Del Carmen MG, Supko JG, Horick NK, Rauh-Hain JA, Clark RM, Campos SM, Krasner CN, Atkinson T, Birrer MJ. Del Carmen MG, et al. Cancer. 2016 Nov 15;122(21):3297-3306. doi: 10.1002/cncr.30196. Epub 2016 Jul 15. Cancer. 2016. PMID: 27421044 Free article. Clinical Trial.
BACKGROUND: The objective of this phase 1 and 2 trial was to identify the appropriate dose of combined carboplatin and pralatrexate for patients with recurrent, platinum-sensitive ovarian, fallopian tube, and primary peritoneal cancer. ...The mean patient age …
BACKGROUND: The objective of this phase 1 and 2 trial was to identify the appropriate dose of combined carboplatin and pralatrexate f …
CD44 standard form expression is correlated with high-grade and advanced-stage ovarian carcinoma but not prognosis.
Zhang J, Chang B, Liu J. Zhang J, et al. Hum Pathol. 2013 Sep;44(9):1882-9. doi: 10.1016/j.humpath.2013.02.016. Epub 2013 May 7. Hum Pathol. 2013. PMID: 23664487 Free PMC article.
The aim of our current study was to clarify the clinical role of CD44 expression in human ovarian carcinoma. Immunohistochemical staining of 483 primary ovarian carcinoma and 27 paired primary and recurrent ovarian carcinoma …
The aim of our current study was to clarify the clinical role of CD44 expression in human ovarian carcinoma. Immunohist …
Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer.
Chelariu-Raicu A, Levenback CF, Slomovitz BM, Wolf J, Bodurka DC, Kavanagh JJ, Morrison C, Gershenson DM, Coleman RL. Chelariu-Raicu A, et al. Int J Gynecol Cancer. 2020 Nov;30(11):1768-1774. doi: 10.1136/ijgc-2020-001863. Epub 2020 Oct 9. Int J Gynecol Cancer. 2020. PMID: 33037105 Clinical Trial.
We conducted a phase Ib/II trial to examine the efficacy, safety, and toxicity of gefitinib, a tyrosine kinase inhibitor, combined with topotecan in women with recurrent ovarian cancer with epidermal growth factor receptor positivity. ...CONCLUSION: Although …
We conducted a phase Ib/II trial to examine the efficacy, safety, and toxicity of gefitinib, a tyrosine kinase inhibitor, combined wi …
Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
Pitakkarnkul S, Tangjitgamol S, Srijaipracharoen S, Manusirivithaya S, Pataradool K, Prutthiphongsit W, Khunnarong J, Thavaramara T. Pitakkarnkul S, et al. Asian Pac J Cancer Prev. 2013;14(4):2421-7. doi: 10.7314/apjcp.2013.14.4.2421. Asian Pac J Cancer Prev. 2013. PMID: 23725151 Free article. Clinical Trial.
BACKGROUND: To study the response rate, toxicity profiles, and survival of refractory or recurrent epithelial ovarian cancer (EOC) patients treated with paclitaxel. ...CONCLUSIONS: Paclitaxel is an active agent for refractory or recurrent EOC. Neutropenia, ne …
BACKGROUND: To study the response rate, toxicity profiles, and survival of refractory or recurrent epithelial ovarian cancer ( …
Bevacizumab combined with chemotherapy in the treatment of recurrence or platinum-refractory ovarian cancer: a retrospective study of 37 cases.
Li Y, Yang Y, Shang YM, Zheng H. Li Y, et al. Indian J Cancer. 2014 Mar;51 Suppl 3:e92-4. doi: 10.4103/0019-509X.154079. Indian J Cancer. 2014. PMID: 25818742 Free article.
Platinum-based regimen was considered as the firs-line chemotherapy treatment modality. But most of the cases developed recurrence or resistance to platinum. The aim of this retrospective study was to evaluate the activity and toxicity of bevacizumab combined with chemothe …
Platinum-based regimen was considered as the firs-line chemotherapy treatment modality. But most of the cases developed recurrence or …
Urothelial carcinoma in both adnexa following perforation during transurethral resection of a non-muscle-invasive bladder tumor: a case report and literature review.
Bus MT, Cordeiro ER, Anastasiadis A, Klioueva NM, de la Rosette JJ, de Reijke TM. Bus MT, et al. Expert Rev Anticancer Ther. 2012 Dec;12(12):1529-36. doi: 10.1586/era.12.136. Expert Rev Anticancer Ther. 2012. PMID: 23253219 Review.
In this article case report of urothelial carcinoma implantation in both adnexa is reported, following a perforation of the bladder wall during a transurethral resection of a bladder tumor. The 81-year-old female patient had an extensive history of multiple recurrent …
In this article case report of urothelial carcinoma implantation in both adnexa is reported, following a perforation of the bladder w …
13 results